How Do Psychedelics Reduce Fear of Death?

This paper is a narrative, evidence‑based argument rather than a primary experimental study. The author reviews qualitative first‑person reports, retrospective surveys, historical clinical studies from the 1960s–70s, and several contemporary quantitative clinical trials and survey studies that measured death anxiety and related constructs. Key psychometric instruments discussed include the Death Transcendence Scale and the Death Acceptance subscale of the Revised Life Attitudes Profile (LAP‑R); other studies used variants of the Death Attitude Profile (DAP‑R) and the Collett‑Lester Fear of Death Scale. The extracted text does not report a formal, systematic search strategy, inclusion/exclusion criteria, or a pre-registered review protocol. Instead, the author synthesises findings from landmark trials (e.g. Griffiths et al., Ross et al.), older psychedelic therapy reports, and several retrospective survey and mediation studies (e.g. Moreton et al., Sweeney et al.). Evidence types therefore span controlled trials with quantitative follow‑ups, correlational survey data, qualitative interviews, and mediation analyses cited in the discussion. Where available, the author integrates specific subscale results and correlational/mediation findings to adjudicate between competing mechanistic accounts, but no meta‑analytic statistical aggregation is reported in the extracted text.

The review finds converging evidence that classic psychedelics can reduce fear of death, but with important heterogeneity in measurement and timing. First‑person reports from clinical trials and anecdotal cases describe profound experiential shifts that participants explicitly link to reduced death anxiety. Historical studies from the 1960s–70s are reported to have measured and often found lasting reductions in death fear, though many of those studies have substantial methodological limitations. Two contemporary trials that explicitly measured attitudes to death produced informative but not uniform results. Griffiths et al. reported significant reductions in death anxiety and increased positive attitudes to death up to six months after a single psilocybin dose; in a healthy volunteer study (N reported as 18 in the extracted text), the only Death Transcendence Scale subscale to show a significant long‑term change at 14 months was the Religious subscale (items probing belief in continuity after death and a controlling Force). Ross et al. reported mixed short‑term effects but noted a significant improvement in death‑related attitudes at the 26‑week follow‑up for the psilocybin‑first group compared with a niacin control. Retrospective surveys also point to links between mystical or ‘‘God‑encounter’’ experiences and reduced fear of death: Griffiths et al. found that 70% of respondents reporting a psychedelic‑induced God encounter agreed their fear of death had been reduced. Moreton et al. reported that reductions in death anxiety following meaningful psychedelic experiences correlated with improved subjective well‑being, and that acute mystical‑type experiences (but not ratings of psychological insight) correlated significantly with reductions in fear of death. In the studies by Moreton et al., mystical‑type experience effects on well‑being were mediated by reductions in death anxiety, whereas psychological insight was not mediated in this way. The author also cites work showing that psychedelic use can shift specific metaphysical beliefs (physicalism, dualism, belief in post‑mortem survival, reincarnation, and paranormal communication). Countervailing evidence discussed by Letheby includes qualitative reports from some participants who emphasised connectedness, acceptance, and psychological insight rather than explicit metaphysical revelations; and findings in other therapeutic contexts where measures of psychological insight predicted outcomes more strongly than mystical‑type experience. The review highlights that these mixed patterns may reflect distinct mechanisms for different outcomes: metaphysical belief shifts appear particularly linked to reductions in death anxiety, while self‑representation changes appear more relevant to reductions in depression and addiction. Throughout, the author stresses that causal inferences remain tentative because many studies are correlational, not all trials measured death anxiety explicitly, and some older studies have methodological shortcomings.

The author interprets the assembled evidence as provisionally supporting the Metaphysical Belief Theory for reductions in fear of death: when psychedelic experiences alleviate existential dread, this commonly occurs via the induction or strengthening of non‑physicalist metaphysical beliefs (for example, beliefs in continuity after death or a higher controlling Force). He contrasts this with Letheby’s self‑unbinding thesis—that psychedelics act primarily by disintegrating rigid self‑representations—and argues that the latter better explains improvements in depression and addiction but does not account as readily for reductions in death anxiety. At a more abstract level, the paper endorses the REBUS model (Relaxed Beliefs Under Psychedelics) as the most plausible general framework. REBUS posits that psychedelics relax high‑level, abstract beliefs about self and world, thereby allowing revision of those beliefs; these revisions can take different specific forms (metaphysical beliefs, self‑related beliefs) depending on context and individual differences. The author cautions against extreme mechanistic pluralism while acknowledging that multiple proximate mechanisms (confrontation with mortality, reduced self‑focus, shifts in metaphysical belief, amplified faith, increased connectedness) may contribute in varying degrees across individuals. Key limitations are acknowledged: the evidence base is not conclusive, many studies did not directly measure fear of death, some relied on retrospective self‑report, and causal mediation remains difficult to establish definitively. The author calls for prospective, carefully designed empirical work—including studies that explicitly recruit and measure responses in avowedly atheistic or physicalist subjects—to discriminate between competing hypotheses. Finally, the paper draws an implication for the ‘‘neuroexistentialist’’ project: if psychedelics typically reduce death anxiety by promoting non‑physicalist beliefs, they are unlikely to serve as a method for reconciling naturalistic atheists to a materialist worldview; instead, they may persuade some users of the falsity of strict naturalism.

The paper concludes that, on balance, the best available evidence tentatively indicates that psychedelics reduce fear of death mainly by promoting non‑physicalist metaphysical beliefs, while reductions in depressive and addictive symptoms are more plausibly driven by changes to self‑representation. REBUS, as an account of belief relaxation and revision at a relatively high level of abstraction, is presented as the most useful general model for accommodating these findings. The author emphasises the provisional nature of this conclusion and recommends further philosophically informed and empirically rigorous research to determine whether a ‘‘naturalistic psychedelic spirituality’’ or other neuroexistentialist solutions are viable.